Chiltern to purchase Theorem Clinical Research
To expand its global reach and scientific expertise
London, UK-based contract research organisation (CRO) Chiltern International is to buy Theorem Clinical Research, a US-based CRO, to expand its global reach, scientific expertise and improve its ability to manage increasingly complex clinical trials.
No financial terms have been revealed.
King of Prussia, PA-based Theorem Clinical Research is a global provider of clinical services with more than 1,500 staff throughout the Americas, Europe and Asia-Pacific and a client base comprising the world’s leading biopharmaceutical and medical device companies.
The company is focused on analytic-based development, combination trials and personal data applications to simplify complex trials.
In key areas, our capabilities will dovetail into current Chiltern operations – this is a mutually beneficial deal
Chiltern employs 2,200 people across 45 countries and has three specialised business units: Chiltern Biopharma, with therapeutic expertise in respiratory, anti-infectives/vaccines, ophthalmology, dermatology and other speciality areas; Chiltern Oncology, led by doctors, scientists and clinicians to manage all phases of haematologic and oncologic clinical drug development; and Chiltern Source, a specialist in tailored relationships for FSP, resourcing and staffing solutions.
'This is a direct response to client demand for a clinical research partner that can provide scientific and operating strengths globally, in a responsive and flexible way,' said Jim Esinhart, CEO of Chiltern.
John Potthoff, President and CEO of Theorem, said: 'Chiltern and Theorem have carved out complementary niches, even across key geographies.
'In key areas, our capabilities will dovetail into current Chiltern operations – this is a mutually beneficial deal.'
The combined company will operate under the Chiltern name and will gain global reach – most notably in China and Japan – as well as new service offerings for medical devices and diagnostics, clinical analytics and clinical supplies.
The transaction is expected to close within the next several weeks.
